Anti-Myelin Oligodendrocyte Glycoprotein (Anti-MOG)
IgG autoantibodies targeting the outermost surface loop of myelin oligodendrocyte glycoprotein (MOG) in the central nervous system.
Standard vs. Optimal Reference RangesTiter
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Within standard population reference range, though above optimal longevity targets.
Negative (<1:20 titer)
General reference distribution across unselected commercial populations.
Negative (undetectable)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Triggers antibody-dependent cell-mediated cytotoxicity (ADCC) directed against myelin sheaths without primary astrocyte lysis.
Differential Diagnosis
Elevated Levels (Anti-MOG High)
- •MOG Antibody-Associated Disease (MOGAD)
- •Pediatric Acute Disseminated Encephalomyelitis (ADEM)
- •Recurrent isolated optic neuritis
Low Levels (Anti-MOG Low)
- •Aquaporin-4 positive NMOSD
- •Classic Multiple Sclerosis
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for Anti-MOG
- Targeted organ system imaging or functional dynamic testing related to mogad demyelinating disease
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Anti-Myelin Oligodendrocyte Glycoprotein - The New England Journal of Medicine (2021). PMID: 34090124
- [2]Anti-MOG Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-Myelin Oligodendrocyte Glycoprotein (Anti-MOG) into overall healthspan optimization.